ClinicalTrials.gg
CompletedNCT06757907Updated Jan 3, 2025

Topical Ganciclovir Versus Systemic Aciclovir in the Treatment of Herpetic Keratitis

An interventional study of Acyclovir 400 MG and Ganciclovir (GCV) in Herpetic Keratitis, sponsored by Al-Azhar University. Completed at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2025-01-03.

Sponsored by Al-Azhar University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Sex
All
01

Study summary

Traditional antiviral treatments, including systemic acyclovir, have shown effectiveness in resolving keratitis but can also lead to complications, including ocular surface toxicity and the development of acyclovir-resistant strains of HSV. Topical ganciclovir 0.15% ophthalmic gel presents a safer alternative for managing herpetic keratitis, offering effective viral suppression with minimal toxicity. This study aims to compare the efficacy and safety of topical ganciclovir versus systemic acyclovir in treating herpetic keratitis, providing valuable insights into optimal management strategies for this condition

02

Conditions studied

  • Herpetic Keratitis

Keywords

  • acyclovir
  • ganciclovir
03

In context

Lead sponsor

Al-Azhar University is the lead sponsor of 535 studies on the registry; 173 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with herpetic keratitis

Exclusion criteria

Exclusion Criteria:

  • Patients with known allergies to ganciclovir or acyclovir
  • Severe ocular surface disease
  • Those who have previously received antiviral therapy for herpetic keratitis within the last month
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    ganciclovir

    Drug: Ganciclovir (GCV)

  • Active comparator
    Systemic acyclovir

    Drug: Acyclovir 400 MG

Interventions

06

What researchers measure

Primary outcomes

  1. Corneal healing

    Heling of the keratitis

    Time frame: At 4 and 6 weeks

Secondary outcomes

  1. Sie effects

    Measuring the percentage of the side effects of the drugs

    Time frame: at 4 and 6 weeks

07

Study locations

1 site
  • Al-Azhar university
    Damietta, Egypt
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in Dec 2024, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2024
First posted
Jan 3, 2025
StartActual
Oct 1, 2024
Primary completionActual
Dec 20, 2024
CompletionActual
Dec 25, 2024
Last update
Jan 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06757907
Responsible party
Ehab Tharwat (Principal Investigator, Al-Azhar University) — Principal investigator
First posted
Jan 3, 2025
Start date
Oct 1, 2024
Primary completion
Dec 20, 2024
Completion
Dec 25, 2024
Last update
Jan 3, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Acyclovir · Ganciclovir

Start the discussion